However, while prospective clinical trials have confirmed the benefit of including those agents into the regimes for advanced CRC, disease progression or therapy-related toxicities might require physicians to switch from anti-EGFR-based therapies to alternative treatments. Here, EGFR is linked to colorectal carcinoma.